Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease

Keyphrases

• Area Cover 20%
• Clinical Trials 40%
• Current Treatment 20%
• Development Effort 20%
• Disease Progression 20%
• Disease-modifying Therapy 20%
• Dopaminergic Therapy 20%
• Drug Development 20%
• Drug Discovery 20%
• Drug Safety 20%
• Early Clinical Development 100%
• Efficacy Data 20%
• Expert Opinion 20%
• Immune Cells 20%
• Motor Symptoms 20%
• Neurodegeneration 20%
• Neuroprotective Effect 20%
• Non-diabetic Population 20%
• Parkinson's Disease 100%
• Pioglitazone 40%
• PPAR Agonists 20%
• Preclinical Data 40%
• Primates 20%
• Prototypic 20%
• Risk Reduction 20%
• Rodents 20%
• Safety Concerns 40%
• Safety Data 20%
• Substantia Nigra 20%
• Thiazolidinediones 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 40%
• Disease 20%
• Disease Exacerbation 20%
• Dopamine Receptor Stimulating Agent 20%
• Down Syndrome 20%
• Drug Development 20%
• Drug Discovery 20%
• Drug Safety 20%
• Nerve Degeneration 20%
• Neuroprotective Agent 20%
• Parkinson's Disease 100%
• Peroxisome Proliferator Activated Receptor 40%
• Pioglitazone 40%
• PPAR Agonist 20%
• Side Effect 20%
• Thiazolidinedione 100%